Edgar Filing: VASOMEDICAL INC - Form 8-K

VASOMEDICAL INC Form 8-K April 04, 2007

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: March 30, 2007 (Date of earliest event reported)

VASOMEDICAL, INC. (Exact name of registrant as specified in its charter)

Delaware	0-18105	11-2871434
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)
180 Linden Avenue, Westbury, New York		11590
(Address of principal executive offices)		(Zip Code)
Registrant's telephone number including area code		(516) 997-4600

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- [] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- [] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- [] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
- [] Pre-commencement communications pursuant to Rule 13e-4c under the Exchange Act (17 CFR 240.13e-4c)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Edgar Filing: VASOMEDICAL INC - Form 8-K

Appointment of Certain Officers; Compensatory Arrangements of Certain officers.

- (b) (i) Effective March 30, 2007, the Company's Vice President, Clinical and Regulatory and Quality Affairs, Thomas Varricchione, resigned as an officer of the Company concurrently with the termination of his employment.
- (ii) On March 30, 2007, the Company received notification from Kenneth W. Rind that he was resigning as a director of the Company, effective immediately. His resignation was for personal reasons and not as a result of any disagreement with the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VASOMEDICAL, INC.

By: /s/ Thomas Glover

Thomas Glover

President and Chief Executive Officer

Dated: April 4, 2007